Taipei, Taiwan, June 6th, 2024 — Lotus Pharmaceuticals (“Lotus”), the largest pharmaceutical company by revenue listed in Taiwan, has announced the acquisition of Thailand business and commercial entity of Teva pharma.
The acquisition is targeted for completion by Q3,2024. Upon finalization, Teva Pharma Thailand will transition into a wholly owned subsidiary of Lotus and Lotus will undertake the sales and marketing of existing products of Teva Pharma Thailand. Following the acquisition, besides further expanding Lotus’ oncology & women’s health products, Lotus will gain access to Teva’s ophthalmic and respiratory portfolio, including leading ophthalmic products such as NATEAR, enabling Lotus to venture into pharmacy channels in Thailand. Following the acquisition, Lotus will expand its Thailand operation team to nearly 100 members, increasing its coverage in both hospital and pharmacy channels.
"This acquisition marks a significant milestone for Lotus as we continue to reinforce our presence across Southeast Asia and is a step towards our aspiration of becoming a leading player in Asia Pacific" remarked Petar Vazharov, CEO of Lotus Pharmaceuticals. "By integrating Teva Pharma Thailand into our operations, we strengthen our generics and specialty product offerings, laying a solid foundation for sustained profit growth in the years ahead. This strategic move underscores our commitment to enhancing healthcare accessibility and our presence in the region."
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
About Teva Pharma Thailand
Located in Bangkok, the commercial operations have a dedicated team of around 80 employees. The business is focused on providing accessible and affordable healthcare solutions in the local market through promoting a broad portfolio of high-quality generic medicines. Key therapeutic areas include Ophthalmology, Respiratory, Immunology, and Oncology.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate Communication
+886 2 2700 5908
investor@lotuspharm.com